Electronic Long Form (ELF) Disclosure of Arthur Caplan, PhD
February 2020

I serve as the unpaid chair of the Compassionate Use Advisory Committees (CompAC), independent panels of internationally recognized medical experts, bioethicists, and patient representatives formed by NYU School of Medicine in collaboration with Janssen Pharmaceuticals. CompAC advises Janssen about requests for “compassionate use” of its investigational medicines. NYU receives administrative funding from Janssen to facilitate the CompAC committees.

I hold a board membership (unpaid) on the foundation/public benefit corporation GE2P2, which sponsors a pro-vaccine policy project, https://centerforvaccineethicsandpolicy.net/about/, and publishes a weekly newsletter on vaccine ethics and policy, and advises industry, NGOs, and global health organizations on ethical access to medicines and vaccines. See http://www.ge2p2.org. I am also a member of its Independent Bioethics Advisory Committee, which advises pharmaceutical and other organizations on the fair and transparent allocation of investigational drugs and provides ethics consultation in other areas (unpaid).

I am a paid member of an advisory board for WIRB/WCG on human subjects research standards. In this role I discuss emerging issues in research ethics with WIRB/WCG leadership at meetings held three times a year. I also give lectures on research ethics topics to WIRB/WCG staff and fellows. The Division of Medical Ethics also has a grant from WIRB/WCG to provide education as part of an annual international research ethics fellows educational program held at NYU Langone.

I was a paid member of an advisory committee on access to pediatric drugs for Biomarin in 2018.

I consulted 2017-2020 for Sangamo, Boehringer, Sanofi, Novartis, Otsuka (all compassionate use–related, all unpaid); FNIH (unpaid); CSL, Glaxo (paid), Fox Chase Cancer Center, and Genae/Cardialen-DSMB (paid); Abeona (paid), Cabella (paid); Stanford UH3 grant DSMB (unpaid); Penn Orphan Disease Center’s Advisory Board (unpaid).

I was compensated for a lecture on research ethics for Pfizer held in NYC in 2018.

***

I have done legal work over the past three years for these law firms/organizations:
St. Cloud Hospital legal department
Sedgwick LLP
The Cochran Firm, Washington, DC (informed consent)
Law Offices of Wade E. Byrd (plaintiff) (informed consent)
Shipman & Goodwin LLP (Hanes v. Yale-New Haven Hospital, defense)
Patterson, Belknap, Webb & Tyler (testified about disclosure requirements of authors in biomedical journals)
LA Folette, Johnson, Dehaas, Fesler & Ames (advice on managing error at IVF clinic)
Parker Waichman LLP,
Nelson Mullins Riley & Scarborough
NY State AG opioid litigation
I have given the following speeches, some for which I was paid or received more than $500 for travel (2018-2020):

“Ethical challenges emerging in research ethics,” McKinsey CMO roundtable, NY, NY
September 4, 2019

“The ethics of compassion and the right to try,” Keynote, Charite BIH Entrepreneurship Summit, Berlin, Germany, June 18, 2019

“Germline gene editing: what, if anything, is unethical about it?” University of Massachusetts Medical School, Worcester, MA, June 6, 2019

“Ethics, AI and healthcare,” Bentley University, Waltham, MA, May 21, 2019

“Ethical challenges of Uterine Transplantation,” Baylor University Medical Center, Dallas, TX, May 3, 2019

“The ethics of hope: can and should patients access unapproved drugs?” Rose Kline lecture, Capital Health Medical Center, Pennington, NJ, May 4, 2019

“Advocacy or stewardship/patient or consumer,” Corser lecture, Gouverneur Hospital, Health and Hospitals Corporation, NY, NY, May 7, 2019

“Expanded access, compassionate use and gene therapy,” NJ BIO, Cranbury, NJ, March 7, 2019

“Ethical challenges of uterine transplantation,” Baylor University Medical Center, Dallas, TX, May 3, 2019

“The ethics of hope: can and should patients access unapproved drugs?” Rose Kline Lecture, Capital Health Medical Center, Pennington, NJ, May 4, 2019

“Advocacy or stewardship/patient or consumer,” Corser lecture, Gouverneur Hospital, Health and Hospitals Corporation, New York, NY, May 7, 2019

Speech at “A Quest for Consensus: Defining Value in Rare Disease Treatment” conference, sponsored by Pfizer (open to public), November 5, 2018

“Ethical challenges in drug development,” Johnson & Johnson Worldwide Pharmaceuticals Division, New York, NY, August 8, 2018 (travel only)

“Judging the past: how history should inform bioethics, from Nuremberg to Jesse Gelsinger,” Eli Lilly Grand Rounds, Indianapolis, IN, May 16, 2018

“What is wrong with right to try and how to make things right for the terminally ill,” Food and Drug Law Institute, annual meeting, Washington, DC, May 4, 2018
“Right to try legislation will not help the dying,” Accelerating Anticancer Agent Development and Validation, annual meeting, Rockville, MD, May 2, 2018

“Research ethics: where have we been, where ought we to go?,” CAREB, Montreal, Quebec, April 28, 2018

“Defining death—lessons from the case of Jahi McMath,” Harvard Medical School, Boston, MA, April 11, 2018

“The lessons of the Charlie Gard case,” Rutgers University School of Medicine, Newark, NJ, February 14, 2018

“The ethics of immunization for dengue,” Sanofi Pasteur, Paris, France, February 7, 2018 (travel only)

“Charlie Gard, Josh Hardy and compassionate use,” Yale-New Haven Bridgeport Hospital, Bridgeport, CT, January 3, 2018

“Ethical challenges of DNR orders,” Memorial Sloan Kettering Cancer Center, New York, NY, January 12, 2018

“The ethics of compassionate use,” Dean’s rounds, Temple University School of Medicine, Philadelphia, PA, January 11, 2018

***

I have done webinars on compassionate use over the past three years for Janssen Pharmaceuticals. I was not paid.

I have done emergency consultations on compassionate use for Trillium, in 2017, for which I did not take compensation, and for CSL Behring, in 2017, for which I did.

I have a paid contract with Web MD/Medscape to record op-eds on topics in medical ethics every month for use on its website.

I tweet frequently at @Arthurcaplan, if you are interested in my political views.

I do not comment on cases or policies involving NYU Langone Health or NYU Grossman School of Medicine.